Sutro Biopharma, Inc. (STRO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Sutro Biopharma, Inc. (STRO) closed at USD 10.52 on 2026-10-14, a change of -5.2 % over the past year, with a market capitalization of USD 190.02M.

Sutro Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sutro Biopharma, Inc. key figures

Previous close

USD 10.52 (2026-10-14)

1-year change

-5.2 %

Market cap

USD 190.02M

Enterprise value

USD 36.46M

P/E ratio (trailing)

-0.64

P/E ratio (forward)

-1.85

EPS (trailing)

-18.02

EPS (forward)

-6.21

PEG ratio

n/a

Price to book

-1.84

Revenue growth

-84.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.93

Employees

128

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sutro Biopharma, Inc. and compare it with other stocks.